Bob Dillman

Bob Dillman

Company: AIVITA Biomedical

Job title: Chief Medical Officer


AV-GBM-1 Patient-Specific Vaccines in Newly Diagnosed Primary Glioblastoma 4:45 pm

AV-GBM-1 product and manufacturing feasibility update Phase 2 safety and survival data including exploratory subset analyses Phase 3 clinical trial considerations and designRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.